$38.78−0.48 (−1.22%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
Xenon Pharmaceuticals (XENE) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
4 figures withheld by our checks. Each blank figure names its reason.
Business engineChoppy: revenue is 59% below its peak, net margin −4612.1%. Worth your attention in FY25: Share count (+81.7%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)—
7.5
FY21→FY25CAGR −20.1%/yr
Net income ($M)▼47.6%
−345.9
FY21→FY25CAGR —
Free cash flow ($M)▼51.7%
−279.9
FY21→FY25CAGR —
Diluted EPS▼44.9%
−4.36
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+81.7%
43.6mn → 79.3mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
Capex
$799.0K
−74.0% YoY in FY25 · 10.7% of revenue.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
-4612¢ of every revenue dollar becomes profit.
Margin trend · direction beats level Gross Operating Net
Net margin -4612.1% is below the sector median.
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
The annual and quarterly statements are struck on share counts that differ by a factor of 0.7944, so per-share figures cannot be compared across the two tables. Each table's per-share figures are on its own share basis.
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | — | 7,500.0 | 0.0 | 0.0 | 9,434.0 | 18,437.0 | — | −20.1% |
Cost of revenue | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Gross profit | — | —A | 0.0 | 0.0 | —A | 18,437.0 | — | — |
Research & development | 371,076.0 | 300,938.0 | 210,394.0 | 167,512.0 | 105,767.0 | 75,463.0 | ▲43.0% | +41.3% |
Selling, general & admin | 94,241.0 | 79,632.0 | 68,904.0 | 46,542.0 | 32,810.0 | 21,967.0 | ▲15.6% | +38.0% |
Total operating expenses | 465,317.0 | 380,570.0 | 279,298.0 | 214,054.0 | 138,577.0 | 97,430.0 | ▲36.3% | +40.6% |
Operating incomefeeds ROC rank | −465,317.0 | −373,070.0 | −279,298.0 | −214,054.0 | −129,143.0 | −78,993.0 | ▼33.6% | — |
Other income, net | 35,808.0 | 28,176.0 | 40,879.0 | 31,369.0 | 3,888.0 | 105.0 | — | — |
Pretax income | −429,509.0 | −344,894.0 | −238,419.0 | −182,685.0 | −125,255.0 | −78,888.0 | ▼44.7% | — |
Income tax | −775.0 | 1,016.0 | −4,089.0 | −292.0 | 118.0 | −6.0 | — | +105.0% (22→25) |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −428,734.0 | −345,910.0 | −234,330.0 | −182,393.0 | −124,936.0 | −78,882.0 | ▼47.6% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | −4.70 | −4.36 | −3.01 | −2.73 | −2.06 | −1.77 | ▼44.9% | — |
Diluted shares (mn) | 99.77 | 79.25 | 77.89 | 66.89 | 60.54 | 43.63 | ▲1.7% | +16.1% |
| Margins | ||||||||
Gross margin | — | —A | — | — | —A | 100.0% | — | — |
Operating margin | — | −4974.3% | — | — | −1368.9% | −428.4% | — | — |
Net margin | — | −4612.1% | — | — | −1324.3% | −427.8% | — | — |
† TTM = trailing four quarters through 2026-09-30.A Withheld: cost of revenue is not on file, so the gross margin is not measured.
5 more years of statements and CSV export are on Premium, and 9 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-26 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Xenon Pharmaceuticals' net income?
Xenon Pharmaceuticals reported net income of −$345.9M in fiscal 2025, a net margin of −4612.1%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

